摘要
目的 探究槐杞黄颗粒辅助贝利尤单抗治疗儿童系统性红斑狼疮(SLE)的疗效及不良反应.方法 选取2020年7月～2023年7月南阳市中心医院收治的100例SLE患儿,采用简单随机化法分为对照A组(n=33)、对照B组(n=33)和研究组(n=34).3组均行常规治疗,在此基础上,给予对照A组贝利尤单抗治疗,给予对照B组槐杞黄颗粒治疗,给予研究组槐杞黄颗粒+贝利尤单抗治疗,均治疗24周.比较3组治疗效果、症状改善情况、治疗前后血清免疫指标[免疫球蛋白G(IgG)、补体C3、补体C4、CD3+T细胞占比、CD4+/CD8+]、炎症指标[白介素-2(IL-2)、血沉(ESR)、C反应蛋白(CRP)]、微小RNA-200(miR-200)、微小RNA-335(miR-335)水平,并统计比较3组治疗期间不良反应.结果 研究组总有效率为97.06％,与对照A组(81.82％)、对照B组(78.79％)比较,差异无统计学意义(均P＞0.05);研究组皮损减轻时间、蛋白尿降低时间、疼痛减轻时间、体温下降时间短于对照A组、对照B组(均P＜0.05);治疗24周后,研究组血清补体C3、补体C4、外周血CD3+T细胞占比、CD4+/CD8+水平高于对照A组、对照B组,IgG水平低于对照A组、对照B组(均P＜0.05);研究组治疗24周后血清IL-2、CRP、外周血ESR水平低于对照A组、对照B组(均P＜0.05);研究组治疗24周后血清miR-200水平高于对照A组、对照B组,血清miR-335水平低于对照A组、对照B组(均P＜0.05);研究组、对照A组、对照B组不良反应发生率分别为8.82％、12.12％、6.06％,组间比较差异无统计学意义(均P＞0.05).结论 槐杞黄颗粒辅助贝利尤单抗治疗儿童SLE的疗效显著,能更有效增强免疫功能,且安全性良好.
Abstract
Objective To investigate the efficacy of Huaiqihuang Granules assisted Beliuzumab in the treatment of children with systemic lupus erythematosus(SLE)and its adverse reaction.Methods A total of 100 children with SLE,who were admit-ted to Nanyang Central Hospital between July 2020 and July 2023,were selected.They were randomly assigned to control group A(n=33),control group B(n=33),and study group(n=34)according to simple randomization method.All three groups re-ceived conventional treatment.In addition,control group A was treated with belimumab,control group B was treated with Hua-iqihuang Granules,and the study group was treated with Huaiqihuang Granules+belimumab.All patients were treated for 24 weeks.The therapeutic effects and symptom improvement of the three groups were compared,as well as the levels of serum im-mune indicators[immunoglobulin G(IgG),complement C3,complement C4,CD3+,CD4+/CD8+],inflammatory factors[inter-leukin-2(IL-2),erythrocyte sedimentation rate(ESR),C-reactive protein(CRP)],microRNA-200(miR-200),microRNA-335(miR-335)before and after treatment.The adverse reactions during treatment were statistically compared among the three groups.Results The difference in total effective rate between the study group(97.06％),control group A(81.82％)and control group B(78.79％)was not significant(all P＞0.05).The study group showed a shorter time for skin lesion reduction,proteinu-ria decrease,pain relief,and body temperature drop compared to the control A and B groups(all P＜0.05).After 24 weeks of treatment,the levels of serum complement C3,complement C4,peripheral blood CD3+,and CD4+/CD8+in the study group were higher than those in control group A and B.Meanwhile,the level of IgG was lower(all P＜0.05).After 24 weeks of treat-ment,the levels of serum IL-2,CRP,and peripheral blood ESR in the study group were lower than those in control group A and B(all P＜0.05).After 24 weeks of treatment,the serum miR-200 level in the study group was higher than that in control group A and B,while the serum miR-335 level was lower than that in control group A and B(all P＜0.05).The incidences of adverse reactions in the study group,control A group and control B group were 8.82％,12.12％and 6.06％,respectively,with no sig-nificant difference between groups(all P＞0.05).Conclusion Huaiqihuang Granules assisted belimumab demonstrates signifi-cant efficacy in the treatment of SLE in children.It can effectively enhance immune function,and exhibit good safety profile.
维普
万方数据